Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
J Pediatr Hematol Oncol ; 45(3): e384-e388, 2023 04 01.
Article in English | MEDLINE | ID: mdl-36730448

ABSTRACT

Multifocal lymphangioendotheliomatosis with thrombocytopenia is a rare disease characterized by progressive multiple vascular lesions and is accompanied by thrombocytopenia. The precise diagnosis of this disease is frequently difficult because of the heterogeneity of the clinical symptoms. We report a case of a male infant who presented with severe thrombocytopenia induced by local inflammation. In addition, enlargement of the extremities with soft tissue and bone involvement without gastrointestinal bleeding was observed. The thrombocytopenia resolved after a combination therapy of sirolimus and prednisolone. Our finding that plasma angiopoietin-2 concentrations reflected the disease status suggests its utility as a biomarker of Multifocal lymphangioendotheliomatosis with thrombocytopenia.


Subject(s)
Blood Coagulation Disorders , Thrombocytopenia , Infant , Humans , Male , Thrombocytopenia/complications , Thrombocytopenia/drug therapy , Thrombocytopenia/diagnosis , Gastrointestinal Hemorrhage/complications , Blood Coagulation Disorders/drug therapy , Sirolimus/therapeutic use , Prednisolone/therapeutic use
2.
Circ J ; 85(10): 1906-1917, 2021 09 24.
Article in English | MEDLINE | ID: mdl-34433758

ABSTRACT

Destination therapy (DT) is the indication to implant a left ventricular assist device (LVAD) in a patient with stage D heart failure who is not a candidate for heart transplantation. The implantable LVAD has been utilized in Japan since 2011 under the indication of bridge to transplant (BTT). After almost 10 year lag, DT has finally been approved and reimbursed in May 2021 in Japan. To initiate the DT program in Japan, revision of the LVAD indication from BTT is necessary. Also, in-depth discussion of caregiver issues as well as end-of-life care is indispensable. For that purpose, we assembled a DT committee of multidisciplinary members in August 2020, and started monthly discussions via web-based communication during the COVID-19 pandemic. This is a summary of the consensus reached after 6 months' discussion, and we have included as many relevant topics as possible. Clinical application of DT has just started, and we are willing to revise this consensus to meet the forthcoming issues raised during real-world clinical experience.


Subject(s)
COVID-19/epidemiology , Consensus , Heart Failure/therapy , Heart Transplantation , Heart-Assist Devices , Pandemics , SARS-CoV-2 , Heart Failure/epidemiology , Humans , Japan/epidemiology
3.
Pathol Int ; 71(8): 500-511, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34125982

ABSTRACT

We elucidated clinicopathological characteristics of giant cell tumor of bone (GCTB) in Japan, and significant clinicopathological factors for predicting local recurrence. Clinicopathological profiles of 213 patients with GCTB (100 male, 113 female) involving extra-craniofacial bones were retrieved. Pathological slides obtained at the initial surgery were reviewed. Fourteen pathological and five clinical features were statistically analyzed to disclose prognostic significance. Patient age ranged from 12-80 years (Average 38.7). Long bones were most frequently affected (86.4%), especially around the knee (62.9%). Histological features are basically similar to those previously reported. Within a follow-up period (24-316 months, average 106.1 months), the local recurrence rate is 29.1%. Metastasis has occurred in 9 patients. Cox regression analysis of representative clinicopathological features shows that younger age, higher mitotic count, smaller zones of stromal hemorrhage, considerable vascular invasion and absence of ischemic necrosis are significant predictors for local recurrence. Initial operative method (curettage) is a significant risk factor in univariate analysis but not by multivariate analysis (P = 0.053). Denosumab administration increases risk but not significantly (P = 0.053). Histone 3.3 G34W immunopositivity is not significant for predicting local recurrence.


Subject(s)
Giant Cell Tumor of Bone/pathology , Neoplasm Recurrence, Local/pathology , Prognosis , Adolescent , Adult , Aged , Aged, 80 and over , Bone Neoplasms/pathology , Child , Curettage , Female , Histones/metabolism , Humans , Japan , Male , Middle Aged , Retrospective Studies , Risk Factors , Young Adult
4.
Cancer Sci ; 111(7): 2635-2646, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32418298

ABSTRACT

Lung cancer is a common type of cancer that represents a health problem worldwide; lung adenocarcinoma (LUAD) is a major subtype of lung cancer. Although several treatments for LUAD have been developed, the mortality rate remains high because of uncontrollable progression. Further biological and clinicopathological studies are therefore needed. Here, we investigated the role of family with sequence similarity 111 member B (FAM111B), which is highly expressed in papillary-predominant LUAD; however, its role in cancer is unclear. An immunohistochemical analysis confirmed that papillary-predominant adenocarcinomas exhibited higher expression of FAM111B, compared with lepidic-predominant adenocarcinomas. Additionally, FAM111B expression was significantly correlated with clinical progression. In vitro functional analyses using FAM111B-knockout cells demonstrated that FAM111B plays an important role in proliferation and cell cycle progression of KRAS-driven LUAD under serum-starvation conditions. Furthermore, FAM111B regulated cyclin D1-CDK4-dependent cell cycle progression by degradation of p16. In summary, we revealed the clinical importance of FAM111B in human tumor tissues, as well as its function as a degradative enzyme. Therefore, FAM111B has potential as a clinicopathological prognostic marker for LUAD.


Subject(s)
Adenocarcinoma of Lung/genetics , Adenocarcinoma of Lung/metabolism , Cell Cycle Proteins/metabolism , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Proto-Oncogene Proteins p21(ras)/genetics , Adenocarcinoma of Lung/pathology , Aged , Aged, 80 and over , Cell Cycle/genetics , Cell Line, Tumor , Cell Movement , Cell Proliferation , Cyclin D/metabolism , Cyclin-Dependent Kinase 4/metabolism , Female , Gene Expression , Gene Knockdown Techniques , Humans , Immunohistochemistry , Male , Middle Aged , Tumor Burden
5.
Pathol Int ; 70(6): 323-329, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32067331

ABSTRACT

The mammalian target of rapamycin (mTOR) inhibitor sirolimus is an effective treatment for difficult-to-treat lymphatic anomalies. However, little is known about the expression of mTOR pathway components in lymphatic anomalies. Here we investigated the expression pattern of mTOR pathway components and their phosphorylated forms (mTOR, p-mTOR, 4EBP1, p-4EBP1, S6K1 and p-S6K1) in normal lymphatic vessels and lymphatic anomalies using immunohistochemistry. We studied 18 patients of lymphatic anomalies, including lymphatic malformation (LM, n = 14), Kaposiform lymphangiomatosis (KLA, n = 2) and Kaposiform hemangioendothelioma (KHE, n = 2). Normal lymphatic vessels expressed 4EBP1, S6K1 and p-S6K1, but not p-4EBP1, mTOR or p-mTOR. The mTOR was detected in all lymphatic anomalies, whereas its activation form p-mTOR was detected in half cases of KLA and KHE but not in LM. All lymphatic anomalies expressed S6K1 and its activated form p-S6K1. The expression of 4EBP1 was also found in all lymphatic anomalies, but its activation was detected in approximately half of them. The activation of mTOR was seen in tumor (KLA and KHE) but not in malformation (LM), whereas the activation of S6K1 and 4EBP1 was seen in all and half of lymphatic anomalies, respectively.


Subject(s)
Lymphatic Diseases/metabolism , Lymphatic System/abnormalities , Lymphatic System/metabolism , TOR Serine-Threonine Kinases/metabolism , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Signal Transduction/physiology , Young Adult
6.
J Infect Chemother ; 26(2): 261-264, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31427201

ABSTRACT

Mycobacterium kansasii is one of the major non-tuberculous mycobacteria species that typically cause pulmonary diseases. M. kansasii is known to cause septic arthritis as an extrapulmonary disease in immunosuppressed patients or chronic skin disease. Herein, we present a case of M. kansasii arthritis involving the elbow of an immunocompetent patient, which was initially suspected to be a soft-tissue tumor. A 70-year-old man presented with a swollen left elbow that had progressed for 18 months with deteriorating arthralgia and limited range of motion. Magnetic resonance imaging revealed filling of the intra-articular space of the elbow and surrounding of the radial head with a soft tissue mass with mixed signal intensity. Initial incisional biopsy was performed via the lateral approach to the elbow joint, and pathological examination of the mass did not reveal any evidence of malignancy. One year after the first operation, arthroscopic surgery was performed to excise the mass following the recurrence of swelling and limited function of the elbow. Pathological examination of the resected synovium revealed epithelioid granulomas containing a multinucleated giant cell and inflammatory cell infiltration, characteristic of mycobacterial infection. M. kansasii was cultured after 2 weeks of incubation of the synovial sample. He experienced full resolution of the swelling and limited function following a combination of synovectomy and multidrug antimycobacterial treatment (rifampin 600 mg/day, clarithromycin 800 mg/day, and ethambutol 750 mg/day). This case highlights the need to consider this rare infection in the differential diagnosis of intra-articular soft tissue tumor-like lesions even in immunocompetent patients.


Subject(s)
Arthritis, Infectious/diagnosis , Elbow Joint/pathology , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium kansasii/isolation & purification , Soft Tissue Neoplasms/diagnosis , Aged , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/complications , Arthritis, Infectious/drug therapy , Clarithromycin/therapeutic use , Diagnosis, Differential , Elbow Joint/diagnostic imaging , Ethambutol/therapeutic use , Humans , Immunocompetence , Magnetic Resonance Imaging , Male , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium Infections, Nontuberculous/drug therapy , Rifampin/therapeutic use , Treatment Outcome
7.
Pediatr Int ; 62(3): 257-304, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32202048

ABSTRACT

The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence-based medicine (EBM) techniques and aimed at improvement of the outcomes. Clinical questions (CQs) were decided based on the important clinical issues. For document retrieval, key words for literature searches were set for each CQ and literature published from 1980 to the end of September 2014 was searched in Pubmed, Cochrane Library, and Japana Centra Revuo Medicina (JCRM). The strengths of evidence and recommendations acquired by systematic reviews were determined following the Medical Information Network Distribution System (MINDS) technique. A total of 33 CQs were used to compile recommendations and the subjects included efficacy of resection, sclerotherapy/embolization, drug therapy, laser therapy, radiotherapy, and other conservative treatment, differences in appropriate treatment due to the location of lesions and among symptoms, appropriate timing of treatment and tests, and pathological diagnosis deciding the diagnosis. Thus, the Japanese Clinical Practice Guidelines for Vascular Anomalies 2017 have been prepared as the evidence-based guidelines for the management of vascular anomalies.


Subject(s)
Hemangioma/therapy , Vascular Malformations/therapy , Arteriovenous Malformations/therapy , Embolization, Therapeutic/methods , Evidence-Based Medicine , Humans , Laser Therapy/methods , Sclerotherapy/methods , Treatment Outcome
8.
Cancer Sci ; 110(5): 1804-1813, 2019 May.
Article in English | MEDLINE | ID: mdl-30907484

ABSTRACT

Endometrioid carcinoma (EC) is one of the most common malignancies of the female genital system. We reported previously that aldehyde dehydrogenase 1 (ALDH1), a predominant isoform of the ALDH family in mammals and a potential marker of normal and malignant stem cells, is related to the tumorigenic potential of EC. We compared the levels of various proteins in human EC cells with high and low ALDH1 expression using shotgun proteomics and found that serum deprivation-response protein (SDPR) was preferentially expressed in cells with high ALDH1 expression. Also known as cavin-2, SDPR is a member of the cavin protein family, which is required for the formation of caveolae. Using SDPR-knockout EC cells generated using the CRISPR/Cas9 system, we revealed that SDPR was correlated with invasion, migration, epithelial-mesenchymal transition, and colony formation, as well as the expression of ALDH1. RNA sequencing showed that integrin-linked kinase (ILK) signaling is involved in the effect of SDPR on ALDH1. Immunohistochemical analysis revealed that the localization of ILK at the cell cortex was disrupted by SDPR knockout, potentially interfering with ILK signaling. Moreover, immunohistochemical analysis of clinical samples showed that SDPR is related to histological characteristics associated with invasiveness, such as poor differentiation, lymphatic invasion, and the microcystic, elongated, and fragmented histopathological pattern. This is, to our knowledge, the first report that SDPR is related to tumor progression.


Subject(s)
Aldehyde Dehydrogenase/metabolism , Carcinoma, Endometrioid/metabolism , Carrier Proteins/metabolism , Endometrial Neoplasms/metabolism , Protein Serine-Threonine Kinases/metabolism , Aldehyde Dehydrogenase 1 Family , Cell Line, Tumor , Cell Movement , Cell Proliferation , Epithelial-Mesenchymal Transition , Female , Gene Expression Regulation, Neoplastic , Humans , Neoplasm Invasiveness , Phosphate-Binding Proteins , Retinal Dehydrogenase , Signal Transduction
9.
J Infect Chemother ; 25(6): 463-466, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30679025

ABSTRACT

Exophiala dermatitidis is a dematiaceous fungus that is increasingly becoming the cause of fungal infection in immunocompromised patients. However, the risk factors and optimal treatment modality for E. dermatitidis infection are unknown to date. Herein, we present a fatal case of E. dermatitidis infection in an adult patient that developed after allogeneic hematopoietic stem cell transplantation for chronic active Epstein-Barr virus infection. The dematiaceous fungus caused a breakthrough fungemia despite prophylactic administration of micafungin. Although the patient was intensively treated with liposomal-amphotericin B and voriconazole, serum level of beta-D-glucan continuously increased, and the patient eventually died because of cerebral hemorrhage. An autopsy found multiple involvements of the fungal infection at the bilateral lungs, thoracic cavities, diaphragm, and thyroid. To the best of our knowledge, this is the first reported case of E. dermatitidis infection involving these tissues as determined via autopsy. This case highlights the importance of attention for Exophiala infection in immunocompromised individuals in those given antifungal therapy with echinocandins.


Subject(s)
Antifungal Agents/therapeutic use , Exophiala/isolation & purification , Immunocompromised Host , Peripheral Blood Stem Cell Transplantation/adverse effects , Phaeohyphomycosis/drug therapy , Adult , Fatal Outcome , Graft vs Host Disease/drug therapy , Graft vs Host Disease/immunology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Lymphoproliferative Disorders/therapy , Male , Phaeohyphomycosis/immunology , Phaeohyphomycosis/microbiology , Phaeohyphomycosis/pathology
10.
Int J Clin Oncol ; 24(10): 1311-1319, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31197555

ABSTRACT

BACKGROUND: Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS. METHODS: We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan-Meier method and the log-rank test were used for survival analyses. RESULTS: Median age of the patients was 61.5 years (range 25-79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327). CONCLUSION: The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/pathology , Neoadjuvant Therapy , Osteosarcoma/pathology , Soft Tissue Neoplasms/pathology , Adult , Aged , Bone Neoplasms/drug therapy , Chemotherapy, Adjuvant , Doxorubicin/administration & dosage , Female , Humans , Ifosfamide/administration & dosage , Male , Middle Aged , Osteosarcoma/drug therapy , Prognosis , Retrospective Studies , Soft Tissue Neoplasms/drug therapy , Survival Rate
11.
Lab Invest ; 98(4): 449-461, 2018 04.
Article in English | MEDLINE | ID: mdl-29467457

ABSTRACT

Adenylosuccinate lyase (ADSL) is an enzyme that plays important roles in de novo purine synthesis. Although ADSL was reported to be upregulated in various malignancies, such as colorectal, breast, and prostate cancer, as well as gliomas, the mechanism by which elevated ADSL expression contributes to cancer has not been elucidated. We previously performed a shotgun proteomics analysis to characterize specific proteins associated with the properties of the aldehyde dehydrogenase (ALDH)-high cell population, which was reported to be involved in tumorigenic potential, and showed that ADSL expression is upregulated in the ALDH-high population of endometrial cancer. Here, we showed that ADSL is involved in endometrial cancer aggressiveness by regulating expression of killer cell lectin-like receptor C3 (KLRC3), which is a receptor expressed on natural killer cells. Immunohistochemical analysis indicated that ADSL expression increased as endometrioid carcinoma specimens became more poorly differentiated and higher degree of primary tumor progression. Knockdown of ADSL in endometrial cancer cells decreased cell proliferation, migration, and invasive capability, and caused the cells to adopt a more rounded shape. DNA microarray analysis and quantitative real-time PCR showed that KLRC3 expression was decreased in ADSL knockdown cells. Knockdown of KLRC3 in endometrial cancer cells resulted in the same phenotype as knockdown of ADSL. Moreover, fumarate, which could be produced by ADSL and was recently shown to be an oncometabolite, recovered KLRC3 expression in ADSL knockdown cells, suggesting that fumarate produced by ADSL could regulate KLRC3 expression. Our findings indicate that ADSL enhances cell proliferation, migration, and invasive capability through regulation of KLRC3 expression by fumarate.


Subject(s)
Adenocarcinoma/enzymology , Adenylosuccinate Lyase/metabolism , Endometrial Neoplasms/enzymology , Fumarates/metabolism , NK Cell Lectin-Like Receptor Subfamily C/metabolism , Cell Line, Tumor , Cell Movement , Cell Proliferation , Female , Humans , Neoplasm Invasiveness
12.
J Epidemiol ; 28(3): 156-160, 2018 Mar 05.
Article in English | MEDLINE | ID: mdl-29129894

ABSTRACT

BACKGROUND: In Japan, the rate of cervical cancer screening is remarkably low, especially among women in their twenties and thirties, when cervical cancer is now increasing dramatically. The aim of this study was to test whether a modified government reminder for 20-year-old women to engage in cervical cancer screening, acting through maternal education and by asking for a maternal recommendation to the daughter to receive the screening, could increase their participation rate. METHODS: In two Japanese cities, 20-year-old girls who had not received their first cervical cancer screening before October of fiscal year 2014 were randomized into two study arms. One group of 1,274 received only a personalized daughter-directed reminder leaflet for cervical cancer screening. In the second group of 1,274, the daughters and their mothers received a combination package containing the same reminder leaflet as did the first group, plus an additional informational leaflet for the mother, which requested that the mother recommend that her daughter undergo cervical cancer screening. The subsequent post-reminder screening rates of these two study arms were compared. RESULTS: The cervical cancer screening rate of 20-year-old women whose mothers received the information leaflet was significantly higher than that for women who received only a leaflet for themselves (11% vs 9%, P = 0.0049). CONCLUSIONS: An intervention with mothers, by sending them a cervical cancer information leaflet with a request that they recommend that their daughter receive cervical cancer screening, significantly improved their daughters' screening rate.


Subject(s)
Early Detection of Cancer/statistics & numerical data , Health Promotion/methods , Mother-Child Relations , Mothers/psychology , Motivation , Nuclear Family/psychology , Uterine Cervical Neoplasms/prevention & control , Female , Humans , Japan , Pamphlets , Young Adult
13.
J Infect Chemother ; 24(12): 975-979, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29804839

ABSTRACT

Staphylococcus aureus as a pathogen in human gestational membranes, a rather rare phenomenon, has recently been the focus of several researches. S. aureus forms biofilms on these membranes and potentially causes chorioamnionitis in pregnant women. We report a case of persistent methicillin-resistant S. aureus (MRSA) bacteremia owing to placental infection, causing chorioamnionitis and preterm birth. A 29-year-old Japanese woman at the 27th gestational week was diagnosed with acute promyelocytic leukemia and underwent all-trans retinoic acid therapy. Soon after hospitalization, the patient presented with persistent MRSA bacteremia of unknown origin. Despite various antimicrobial therapies, she experienced 12 MRSA bacteremia episodes over 6 weeks. However, after child birth, MRSA bacteremia disappeared without any complications. A pathologic examination of her placenta revealed placenta abscess, resulting in a diagnosis of MRSA-associated chorioamnionitis. Molecular analysis proved that a single MRSA strain (SCCmec Type IVa), which tested negative for Panton-Valentine leukocidin and toxic shock syndrome toxin-1, caused the obstinate infection. We should be aware that persistent MRSA bacteremia in pregnant women can originate from placental abscess.


Subject(s)
Abdominal Abscess/diagnosis , Bacteremia/diagnosis , Methicillin-Resistant Staphylococcus aureus/genetics , Placenta/microbiology , Staphylococcal Infections/diagnosis , Abdominal Abscess/blood , Abdominal Abscess/complications , Abdominal Abscess/drug therapy , Adult , Bacteremia/drug therapy , Bacterial Toxins/genetics , Chorioamnionitis/blood , Chorioamnionitis/diagnosis , Chorioamnionitis/drug therapy , Exotoxins/genetics , Female , Humans , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/drug therapy , Leukocidins/genetics , Methicillin-Resistant Staphylococcus aureus/drug effects , Pancytopenia , Placenta/pathology , Pregnancy , Staphylococcal Infections/drug therapy , Tretinoin/therapeutic use
14.
Kyobu Geka ; 71(7): 532-537, 2018 Jul.
Article in Japanese | MEDLINE | ID: mdl-30042258

ABSTRACT

From 2005, 124 patients have received implantable left ventricular assist device (iVAD) in our institute, including HeartMate II (84), EVAHEART (17), Jarvik2000 (13), DuraHeart (9), HVAD (1). At February 2018, 60 patients were waiting for heart transplant with iVAD support. Multi-specialist team consisted of clinical engineer, VAD management specialist, nurse, transplant coordinator for recipient and physicians provide patients care. Thirty one percents returned to their social activity after iVAD implantation. 73% patients required rehospitalization for more than 1 time. Overall frequency of rehospitalization was 1.43 events per patient-year. Driveline infection was the most frequent reason and tended to repeat, accounted for 41% of overall rehospitalization. To reduce skin trouble around the driveline exit site causing driveline infection, we made a skin care outpatient clinic, cooperating with a certified nurse in wound, ostomy, and continence nursing (WOC). Besides, we utilize smartphones for remote advising system for patients to facilitate early diagnosis and precise care for driveline infection. A self-anticoagulation management device( Coag-check XS personal) enable us to give adequate anticoagulation therapy and to minimize bleeding and thromboembolic event. Additionally, establishment of psychosocial care promote patient's recovery of social status. With those strategies in outpatient care, we are trying to achieve successful quality of life of iVAD patients.


Subject(s)
Ambulatory Care , Heart Transplantation/statistics & numerical data , Heart-Assist Devices/statistics & numerical data , Patient Readmission/statistics & numerical data , Waiting Lists , Anticoagulants/therapeutic use , Heart-Assist Devices/adverse effects , Humans , Patient Care Team/statistics & numerical data , Prosthesis Implantation , Quality of Life , Surgical Wound Infection/diagnosis , Surgical Wound Infection/prevention & control
16.
J Stroke Cerebrovasc Dis ; 26(6): e108-e110, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28366663

ABSTRACT

We present an autopsy case of repetitive stroke due to tumor emboli, indistinguishable from thromboembolism with a hypercoagulable state in its clinical course. A 72-year-old man diagnosed with stage IVA oropharyngeal squamous cell carcinoma received chemoradiotherapy. Follow-up imaging revealed mediastinal lymph nodes and pulmonary metastasis. One year later, the patient experienced right arm weakness, and brain magnetic resonance imaging showed acute ischemic lesions in multiple vascular territories. He was diagnosed with paradoxical cerebral embolism due to cancer-associated venous thrombosis and treated with rivaroxaban. However, newly developed cerebral infarcts were confirmed 1 month later. Then, rivaroxaban treatment was switched to subcutaneous unfractionated heparin injection. He was admitted again for stroke recurrence and died of respiratory failure 8 days after admission. Autopsy demonstrated pulmonary metastasis invading the veins and tumor emboli in the culprit cerebral arteries. D-dimer was kept constant at a slightly higher level, ranging from 1 to 3 µg/mL during the course of recurrence. We should consider tumor embolism in the differential diagnosis of recurrent stroke along with pulmonary tumor and resistance to heparin preparations with unchanged D-dimer levels.


Subject(s)
Carcinoma, Squamous Cell/secondary , Head and Neck Neoplasms/pathology , Intracranial Embolism/etiology , Lung Neoplasms/secondary , Neoplastic Cells, Circulating/pathology , Oropharyngeal Neoplasms/pathology , Stroke/etiology , Aged , Anticoagulants/therapeutic use , Autopsy , Biomarkers/blood , Biopsy , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/therapy , Diffusion Magnetic Resonance Imaging , Fatal Outcome , Fibrin Fibrinogen Degradation Products/metabolism , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/therapy , Humans , Intracranial Embolism/diagnosis , Intracranial Embolism/drug therapy , Lung Neoplasms/complications , Lung Neoplasms/therapy , Lymphatic Metastasis , Male , Neoplasm Staging , Oropharyngeal Neoplasms/complications , Oropharyngeal Neoplasms/therapy , Recurrence , Respiratory Insufficiency/etiology , Squamous Cell Carcinoma of Head and Neck , Stroke/diagnosis , Stroke/drug therapy , Treatment Outcome
17.
Cancer Sci ; 107(9): 1345-52, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27348205

ABSTRACT

Endometrioid carcinoma (EC) is one of the most common malignancies of the female genital system. Although the behavior of EC ranges from an excellent prognosis to aggressive disease with a poor outcome, the factors that determine its diversity have not been determined. Here, we show that S100A4, a calcium-binding protein of the EF-hand type, is correlated with the proliferation and invasion ability of EC. We demonstrated previously that EC cells with high aldehyde dehydrogenase (ALDH) activity were more tumorigenic than ALDH-lo cells. Screening by shotgun proteomics demonstrated that the expression level of S100A4 in ALDH-hi EC cells was significantly higher than that in ALDH-lo cells. S100A4-knockout cells generated by the CRISPR/Cas9 system showed reduced proliferation and invasion. These cells showed impaired AKT phosphorylation and matrix metalloproteinase-2 activation, accounting for their impaired proliferation and invasion, respectively. Furthermore, in clinical EC samples, elevated expression of S100A4 was highly related to myometrial and lymphatic invasion in well to moderately differentiated EC. Notably, strong and diffuse expression of S100A4 was observed in tumor tissues with a microcystic, elongated and fragmented ("MELF") pattern, which is associated with a highly invasive EC phenotype. Collectively, our results demonstrate not only that high expression of S100A4 contributes to an aggressive phenotype of EC, but also that its elevated expression is closely related to the MELF histopathological pattern.


Subject(s)
Carcinoma, Endometrioid/genetics , Carcinoma, Endometrioid/pathology , S100 Calcium-Binding Protein A4/genetics , Aldehyde Dehydrogenase/metabolism , Carcinoma, Endometrioid/metabolism , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , Female , Gene Expression , Gene Knockout Techniques , Humans , Immunohistochemistry , Matrix Metalloproteinase 2/metabolism , Neoplasm Invasiveness , Protein Binding , Proto-Oncogene Proteins c-akt/metabolism , S100 Calcium-Binding Protein A4/metabolism , Signal Transduction
18.
Br J Cancer ; 114(5): 554-61, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26889980

ABSTRACT

BACKGROUND: Ovarian and endometrial high-grade serous carcinomas (HGSCs) have similar clinical and pathological characteristics; however, exhaustive protein expression profiling of these cancers has yet to be reported. METHODS: We performed protein expression profiling on 14 cases of HGSCs (7 ovarian and 7 endometrial) and 18 endometrioid carcinomas (9 ovarian and 9 endometrial) using iTRAQ-based exhaustive and quantitative protein analysis. RESULTS: We identified 828 tumour-expressed proteins and evaluated the statistical similarity of protein expression profiles between ovarian and endometrial HGSCs using unsupervised hierarchical cluster analysis (P<0.01). Using 45 statistically highly expressed proteins in HGSCs, protein ontology analysis detected two enriched terms and proteins composing each term: IMP2 and MCM2. Immunohistochemical analyses confirmed the higher expression of IMP2 and MCM2 in ovarian and endometrial HGSCs as well as in tubal and peritoneal HGSCs than in endometrioid carcinomas (P<0.01). The knockdown of either IMP2 or MCM2 by siRNA interference significantly decreased the proliferation rate of ovarian HGSC cell line (P<0.01). CONCLUSIONS: We demonstrated the statistical similarity of the protein expression profiles of ovarian and endometrial HGSC beyond the organs. We suggest that increased IMP2 and MCM2 expression may underlie some of the rapid HGSC growth observed clinically.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Endometrioid/metabolism , Endometrial Neoplasms/metabolism , Minichromosome Maintenance Complex Component 2/metabolism , Neoplasms, Cystic, Mucinous, and Serous/metabolism , Ovarian Neoplasms/metabolism , Proteomics , RNA-Binding Proteins/metabolism , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Cell Proliferation/genetics , Cluster Analysis , Female , Gene Knockdown Techniques , Humans , Immunohistochemistry , Middle Aged , Minichromosome Maintenance Complex Component 2/genetics , Neoplasms, Cystic, Mucinous, and Serous/genetics , Ovarian Neoplasms/genetics , RNA-Binding Proteins/genetics
19.
J Obstet Gynaecol Res ; 42(12): 1802-1807, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27641631

ABSTRACT

AIM: In Japan, the rate of routine cervical cancer screening is quite low, and the incidence of cervical cancer has recently been increasing. Our objective was to investigate ways to effectively influence parental willingness to recommend that their 20-year-old daughters undergo cervical cancer screening. METHODS: We targeted parents whose 20-year-old daughters were living with them. In fiscal year 2013, as usual, the daughter received a reminder postcard several months after they had received a free coupon for cervical cancer screening. In fiscal year 2014, the targeted parents received a cervical cancer information leaflet, as well as a cartoon about cervical cancer to show to their daughters, with a request that they recommend to their daughter that she undergo cervical cancer screening. The subsequent screening rates for fiscal years 2013 and 2014 were compared. RESULTS: The cervical cancer screening rate of 20-year-old women whose parents received the information packet in fiscal year 2014 was significantly higher than for the women who, in fiscal year 2013, received only a simple reminder postcard (P < 0.001). As a result, the total screening rate for 20-year-old women for the whole of the 2014 fiscal year was significantly increased over 2013 (P < 0.001). CONCLUSION: For the first time, we have shown that the parents of 20-year-old daughters can be motivated to recommend that their daughters receive their first cervical cancer screening. This was achieved by sending a cervical cancer information leaflet and a cartoon about cervical cancer for these parents to show to their daughters. This method was significantly effective for improving cervical cancer screening rates.


Subject(s)
Early Detection of Cancer/statistics & numerical data , Marketing of Health Services , Parents , Patient Acceptance of Health Care/statistics & numerical data , Uterine Cervical Neoplasms/prevention & control , Adult , Female , Humans , Japan , Nuclear Family , Young Adult
20.
Pathol Int ; 65(7): 388-92, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25941021

ABSTRACT

The anti-Hu antibody is one of the most famous onco-neural antibodies related to paraneoplastic neurological syndrome, and is associated with small cell lung carcinoma in most cases. Here, we report a case of poorly differentiated hepatocellular carcinoma accompanied by paraneoplastic peripheral neuropathy positive for the anti-Hu antibody. Image inspection before operation revealed that no tumors were found in organs other than the liver, including lung, and that the liver tumor had no metastatic lesion. The liver tumor showed histological appearance of poorly differentiated carcinoma with cartilaginous metaplasia and partial blastoid cell appearance. Most tumor cells presented trabecular-like structure lined by sinusoidal vessels. Immunohistochemically, the tumor cells were positive for low molecular weight cytokeratin and vimentin, partially positive for cytokeratin 19 and CD56, but negative for synaptophysin, chromogranin A and alpha-fetoprotein. Based on the trabecular-like morphology and the results of immunohistochemical staining, we concluded that the tumor was diagnosed as poorly differentiated hepatocellular carcinoma. Anti-Hu antibody-positive paraneoplastic peripheral neuropathy accompanied with liver tumor is extremely rare as far as is known. The presented case indicates that poorly differentiated carcinoma has the potential to be the responsible lesion of anti-Hu antibody-positive paraneoplastic neurological syndrome and systemic work-up is important for the management of this neurological disorder.


Subject(s)
Carcinoma, Hepatocellular/pathology , Cell Differentiation/physiology , Liver Neoplasms/pathology , Paraneoplastic Polyneuropathy/pathology , Paraneoplastic Syndromes/pathology , Aged , Antibodies/immunology , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/diagnosis , Diagnosis, Differential , ELAV Proteins/immunology , Female , Humans , Liver Neoplasms/diagnosis , Paraneoplastic Polyneuropathy/diagnosis , Paraneoplastic Syndromes/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL